You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

386 Results
Drug
Other Name(s): Rituxan® , Truxima™ , Riximyo™ , Ruxience™ , Riabni™
Quick Link(s): Drug Monograph, Patient Info Sheet
Oct 2023
Drug
Other Name(s): Ifex® (multiple brands available)
Quick Link(s): Drug Monograph, Patient Info Sheet
Aug 2016
Drug
Other Name(s): Yervoy®
Quick Link(s): Drug Monograph, Patient Info Sheet
Aug 2024
Drug
Other Name(s): Stivarga®
Quick Link(s): Drug Monograph, Patient Info Sheet
Nov 2023
Drug
Other Name(s): Istodax®
Quick Link(s): Drug Monograph, Patient Info Sheet
Mar 2023
Drug
Other Name(s): Imbruvica®
Quick Link(s): Drug Monograph, Patient Info Sheet
Feb 2023
Drug
Other Name(s): Cyramza®
Quick Link(s): Drug Monograph, Patient Info Sheet
Mar 2023
Drug
Other Name(s): Zydelig™
Quick Link(s): Drug Monograph, Patient Info Sheet
Feb 2022
Drug
Other Name(s): Ninlaro™
Quick Link(s): Drug Monograph, Patient Info Sheet
Jun 2019
Regimen
Cancer Type:
Gastrointestinal, 
Gastrointestinal Stromal Tumours, 
Sarcoma, 
GIST
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant
Funding:
ODB - General Benefit
    iMAtinib - Refer to listed Health Canada indications for generic imatinib formulations. Patients must meet generic substitution policies for access to Gleevec®
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
iMAtinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Oct 2024
Regimen
Cancer Type:
Gastrointestinal, 
Gastrointestinal Stromal Tumours, 
Sarcoma, 
GIST
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    iMAtinib - Refer to listed Health Canada indications for generic imatinib formulations. Patients must meet generic substitution policies for access to Gleevec®
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
iMAtinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Oct 2024
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Myeloid (CML)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    iMAtinib - Refer to listed Health Canada indications for generic imatinib formulations. Patients must meet generic substitution policies for access to Gleevec®
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
iMAtinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Oct 2024

Pages